Market Cap 6.19M
Revenue (ttm) 0.00
Net Income (ttm) -7.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 98,556
Avg Vol 91,110
Day's Range N/A - N/A
Shares Out 4.30M
Stochastic %K 49%
Beta -2.05
Analysts Strong Sell
Price Target $17.00

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 533 1469
Address:
259 Liberty Avenue, Staten Island, United States
ExploringTrades
ExploringTrades Aug. 4 at 4:43 PM
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $PUSA $ACXP Pola
0 · Reply
MarketForecasting
MarketForecasting Aug. 3 at 5:10 PM
$ACXP what fools these stooges are , putting the cart before the horse.
0 · Reply
STACKD0E
STACKD0E Aug. 3 at 12:35 PM
$ACXP 👁
0 · Reply
ballyhooo
ballyhooo Aug. 3 at 12:19 PM
$ACXP just approve it already...it actually works!
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jul. 22 at 2:45 PM
$ACXP ACXP is going to begin to start the process of starting to begin initiating the process of beginning to start the process of starting a trial to enroll multiple recurring CDI patients. Remember, multiple recurring patients comprise under 5% of the population of CDI patients and Luci couldn't even find enough primary episode patients to do a 72 person trial. He did 32 instead, and it took 2.3 years from first patient enrolled to "study stopped for success". Simple math says that if the multiple recurrence patients are 5% of the primary episode patients in terms of population size, it will be 20X harder for Luci to recruit and enroll. 20X * (20 patients/32 patients)*2.3 years = 28.75 years. It will take Luci 28.75 years to finish this study. Let's overlook the fact that he is now out of money, he is older, his two partners are older, he is still fat, lets overlook all of this and assume that his recruiting yield quadruples for no reason whatsoever. It still take 7 years. FU LUCI.
2 · Reply
milesdonaldson
milesdonaldson Jul. 17 at 6:15 PM
$ACXP https://www.linkedin.com/posts/david-luci-acurx_acurx-pharmaceuticals-has-initiated-startup-share-7482430776429670400-fu4k/?utm_source=share&utm_medium=member_desktop&rcm=ACoAABT7ZCgBOy3DudyxFBvHlx7Q_iM46UBcZAM
0 · Reply
NotBornYesterday
NotBornYesterday Jul. 14 at 7:25 PM
$ACXP Up to 24 co-sponsors in House and recently introduced in Senate (w/Gillibrand in NY where company is located - i doubt this is a coincidence). Bipartisan sponsorship. Very few publicly traded pure play development stage antimicrobial stocks available to gain exposure.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jul. 9 at 7:33 PM
$ACXP will have to wait until next week for the all time low. No matter, Luci gets paid while incinerating shareholders.
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jul. 5 at 11:02 PM
Small-Caps with Catalysts this week: 👇👇 ( $MMA, $GAME, $NYXH, $ACXP, etc...) #NASDAQ #NYSE
0 · Reply
marketmoney402
marketmoney402 Jun. 29 at 2:10 PM
0 · Reply
Latest News on ACXP
Acurx’s ibezapolstat shows microbe preservation efficacy

2026-07-14T12:10:22.000Z - 21 days ago

Acurx’s ibezapolstat shows microbe preservation efficacy


Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026


Acurx Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Quarterly report: Q1 2026


Acurx Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Earnings release: Q1 2026


Acurx files to sell 1.65M shares of common stock for holders

2026-05-04T20:30:19.000Z - 3 months ago

Acurx files to sell 1.65M shares of common stock for holders


Acurx files to sell 1.3M shares of common stock for holders

2026-05-04T20:29:36.000Z - 3 months ago

Acurx files to sell 1.3M shares of common stock for holders


New to The Street announce re-signing of Acurx Pharmaceuticals

2026-04-07T13:33:21.000Z - 4 months ago

New to The Street announce re-signing of Acurx Pharmaceuticals


Acurx price target lowered to $10 from $20 at Alliance Global

2026-03-13T16:50:20.000Z - 5 months ago

Acurx price target lowered to $10 from $20 at Alliance Global


Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025


Acurx Pharmaceuticals Earnings release: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Acurx Pharmaceuticals Earnings release: Q4 2025


Acurx Pharmaceuticals Annual report: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Acurx Pharmaceuticals Annual report: Q4 2025


Acurx announces new ibezapolstat clinical trial program

2026-03-09T12:05:07.000Z - 5 months ago

Acurx announces new ibezapolstat clinical trial program


Acurx files to sell 750,000 shares of common stock for holders

2026-02-02T21:50:10.000Z - 6 months ago

Acurx files to sell 750,000 shares of common stock for holders


Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025


Acurx Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Acurx Pharmaceuticals Earnings release: Q3 2025


Acurx Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Acurx Pharmaceuticals Quarterly report: Q3 2025


Acurx announces publication of results from ibezapolstat study

2025-11-10T13:10:40.000Z - 9 months ago

Acurx announces publication of results from ibezapolstat study


Acurx files to sell 585,000 shares of common stock for holders

2025-10-20T21:30:17.000Z - 10 months ago

Acurx files to sell 585,000 shares of common stock for holders


Acurx Pharmaceuticals Registration statement: Registration Filing

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing


Acurx Pharmaceuticals Slides: Conference presentation

Oct 20, 2025, 7:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Slides: Conference presentation


Acurx granted new patent for DNA Polymerase IIIC Inhibitors

2025-10-09T11:36:04.000Z - 10 months ago

Acurx granted new patent for DNA Polymerase IIIC Inhibitors


Acurx Pharmaceuticals Slides: Study update presentation

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Slides: Study update presentation


Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025


Acurx Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q2 2025


Acurx Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q2 2025


Acurx Pharmaceuticals Proxy statement: Proxy Filing

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 31, 2025, 9:25 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split


Acurx Pharmaceuticals Proxy statement: Proxy Filing

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing


Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025


Acurx Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q1 2025


Acurx Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q1 2025


Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024


Acurx Pharmaceuticals Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q4 2024


Acurx Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Annual report: Q4 2024


Acurx Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2024


Acurx Pharmaceuticals Earnings release: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals Earnings release: Q3 2024


Acurx Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q3 2024


ExploringTrades
ExploringTrades Aug. 4 at 4:43 PM
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $PUSA $ACXP Pola
0 · Reply
MarketForecasting
MarketForecasting Aug. 3 at 5:10 PM
$ACXP what fools these stooges are , putting the cart before the horse.
0 · Reply
STACKD0E
STACKD0E Aug. 3 at 12:35 PM
$ACXP 👁
0 · Reply
ballyhooo
ballyhooo Aug. 3 at 12:19 PM
$ACXP just approve it already...it actually works!
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jul. 22 at 2:45 PM
$ACXP ACXP is going to begin to start the process of starting to begin initiating the process of beginning to start the process of starting a trial to enroll multiple recurring CDI patients. Remember, multiple recurring patients comprise under 5% of the population of CDI patients and Luci couldn't even find enough primary episode patients to do a 72 person trial. He did 32 instead, and it took 2.3 years from first patient enrolled to "study stopped for success". Simple math says that if the multiple recurrence patients are 5% of the primary episode patients in terms of population size, it will be 20X harder for Luci to recruit and enroll. 20X * (20 patients/32 patients)*2.3 years = 28.75 years. It will take Luci 28.75 years to finish this study. Let's overlook the fact that he is now out of money, he is older, his two partners are older, he is still fat, lets overlook all of this and assume that his recruiting yield quadruples for no reason whatsoever. It still take 7 years. FU LUCI.
2 · Reply
milesdonaldson
milesdonaldson Jul. 17 at 6:15 PM
$ACXP https://www.linkedin.com/posts/david-luci-acurx_acurx-pharmaceuticals-has-initiated-startup-share-7482430776429670400-fu4k/?utm_source=share&utm_medium=member_desktop&rcm=ACoAABT7ZCgBOy3DudyxFBvHlx7Q_iM46UBcZAM
0 · Reply
NotBornYesterday
NotBornYesterday Jul. 14 at 7:25 PM
$ACXP Up to 24 co-sponsors in House and recently introduced in Senate (w/Gillibrand in NY where company is located - i doubt this is a coincidence). Bipartisan sponsorship. Very few publicly traded pure play development stage antimicrobial stocks available to gain exposure.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jul. 9 at 7:33 PM
$ACXP will have to wait until next week for the all time low. No matter, Luci gets paid while incinerating shareholders.
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jul. 5 at 11:02 PM
Small-Caps with Catalysts this week: 👇👇 ( $MMA, $GAME, $NYXH, $ACXP, etc...) #NASDAQ #NYSE
0 · Reply
marketmoney402
marketmoney402 Jun. 29 at 2:10 PM
0 · Reply
ChicagoJoe20
ChicagoJoe20 Jun. 26 at 4:32 PM
$ACXP remember when they wanted BTC? 🙄
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jun. 25 at 6:01 PM
$ACXP all time low tomorrow? No matter, Luci and friends still getting paid.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jun. 16 at 2:46 PM
$ACXP tick tock Luci. shut the door
0 · Reply
Archnemesis
Archnemesis Jun. 11 at 4:07 PM
$ACXP I think its the bottom here. Sorry for the fuzzy pic.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jun. 8 at 5:33 PM
$ACXP all time low this week.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Jun. 5 at 4:29 PM
$ACXP you suck Luci.
0 · Reply
MilsLearning
MilsLearning May. 22 at 12:07 PM
$ACXP 🖕🩳🔥
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 6:49 PM
0 · Reply
focafoca99
focafoca99 May. 19 at 4:38 PM
$ACXP explains FDA's new CDI guidance that could speed approval for its ibezapolstat antibiotic.
1 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN May. 15 at 5:21 PM
$ACXP should see under a dollar in a month at current rate of decline. Luci you suck.
1 · Reply
NotBornYesterday
NotBornYesterday May. 15 at 12:54 PM
$ACXP bill now up to 20 co-sponsors. https://www.congress.gov/bill/119th-congress/house-bill/7352/cosponsors?pageSort=lastToFirst&loclr=cga-bill
1 · Reply